A Study Evaluating Good Idea on Glucose Homeostasis in a Healthy Population

A Multi-centre Randomized, Double-blind, Placebo-controlled, Crossover, Proof-of-concept Study to Evaluate the Efficacy and Safety of Good IdeaTM on Glucose Homeostasis in a Healthy Population

A crossover design to evaluate the safety and efficacy of GoodIdea TM (trademark) on glucose homeostasis in a healthy population. Eligible participants will be given either the GoodIdea drink or placebo and a standardized meal and will consume both in approximately 15 minutes. Blood will be drawn at several time points over a 3 hour period to determine the study objectives. After a 7-day washout, the participants will come back to the clinic and and complete the visit consuming the opposite product given at the previous visit. The primary objective is to see the difference of the two-hour iAUC for intravenous blood glucose between the active product (GoodIdea) and the placebo following a standardized meal.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Dietary supplement: GoodIdea; Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • London, Ontario, Canada, N6A 5R8
      • KGK Synergize Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female 18 to 50 years of age
• BMI 25-29.9 (±0.5) kg/m²
• Female participant is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR
• Females of childbearing potential who agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
• Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
• Double-barrier method
• Intrauterine devices
• Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
• Vasectomy of partner (shown successful as per appropriate follow-up)
• White North American (should include Hispanic, non-Hispanic, Aboriginal and Asian) or African American
• Stable body weight defined as no more than ± 3 kg change during the last 2 months
• Agree to maintain consistent dietary habits and physical activity levels for the duration of the study
• Self-perceived general good health as per the general health questionnaire
• Fasting blood glucose < 6.1 mmol/L at screening
• Healthy as determined by laboratory results and medical history
• Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
• Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

• Women who are pregnant, breast feeding, or planning to become pregnant during the trial
• Any medical condition(s) or medication(s) known to significantly affect glucose metabolism. Significance to be assessed by the Qualified Investigator
• Has undergone procedures that requires cleansing of the bowel, such as colonoscopy or barium enema within three months prior to randomization
• Type I or Type II diabetes
• Use of over-the-counter medication or natural health products that affect glucose metabolism is prohibited within 2 weeks of enrollment and during this study
• Use of anti-biotics within 2 weeks of enrollment
• Use of probiotic supplements within 2 weeks of enrollment
• Use of cholesterol lowering medications
• Use of blood pressure medications
• Use of over-the-counter decongestants that contain ephedrine or pseudoephedrine within 2 weeks of enrollment
• Use of acute or over the counter medications within 72 h of test product consumption
• Use of Tricyclic antidepressants or any other medication that will modify bowel function
• Metabolic diseases and chronic gastrointestinal diseases (IBS, Crohns etc.)
• Allergy to test product or placebo ingredients
• Participants restricted to a vegetarian or vegan diet
• Intolerance to lactose or gluten
• Irregular dietary habits, including: intermittent fasting, regularly skipped meals, and individuals who do not typically eat breakfast
• Any form of acute infection within 2 weeks of enrollment
• Individuals who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis)
• History of gastrointestinal dysfunction or surgery that may influence digestion or absorption
• History of blood/bleeding disorders
• Individuals who are averse to venous catheterization or capillary blood sampling
• Current diagnosis of cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
• Individuals who have planned surgery during the course of the study
• Alcohol or drug abuse within the last 6 months
• Currently active smokers (tobacco products, and e-cigarettes) or smoking within the 6 months of enrollment
• Blood or plasma donation in the past 2 months
• Participants planning to donate blood during, or within 30 days following completion of the study
• Use of medical marijuana
• History of, or current, psychiatric disease
• Unstable medical conditions as determined by Qualified Investigator
• Clinically significant abnormal laboratory results at screening
• Participation in a clinical research trial within 30 days prior to randomization
• Individuals who are cognitively impaired and/or who are unable to give informed consent
• Any other condition which in the Qualified Investigator's opinion may adversely affect the individual's ability to complete the study or its measures or which may pose significant risk to the individual
• Medical or psychological condition that in the Qualified Investigator's opinion could interfere with study participation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Consume GoodIdea at Visit 2 and Placebo at Visit 3	Dietary supplement: GoodIdea; Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.; Other: Placebo; Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
Experimental: Consume Placebo at Visit 2 and GoodIdea at Visit 3	Dietary supplement: GoodIdea; Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.; Other: Placebo; Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The difference of the two-hour iAUC (0 - 120 min) for intravenous blood glucose between Good IdeaTM and the placebo following a standardized meal.	0 - 120 minutes

Secondary Outcome Measures

Outcome Measure	Time Frame
The difference of the two-hour iAUC (0 - 120 min) for capillary blood glucose between Good IdeaTM and the placebo following a standardized meal.	0 -120 minutes
The difference in the two-hour Cmax, (0 - 120 min) of capillary glucose between Good IdeaTM and the placebo following a standardized meal.	0 - 120 minutes
The difference in the two-hour Tmax (0 - 120 min) of capillary glucose between Good IdeaTM and the placebo following a standardized meal.	0 - 120 minutes
The difference in the two-hour iAUC (0 - 120 min) intravenous insulin iAUC between Good IdeaTM and the placebo following a standardized meal.	0 - 120 minutes
The difference in the two-hour Cmax (0 - 120 min) of intravenous glucose and insulin between Good IdeaTM and the placebo following a standardized meal.	0 - 120 minutes
The difference in the two-hour Tmax (0 - 120 min) of intravenous glucose and insulin between Good IdeaTM and the placebo following a standardized meal.	0 - 120 minutes
The difference in the three-hour iAUC (0 - 180 min) for intravenous blood glucose and insulin between Good IdeaTM and the placebo following a standardized meal.	0 - 180 minutes
The difference in the three-hour Cmax (0 - 180 min) of intravenous glucose and insulin between Good IdeaTM and the placebo following a standardized meal.	0 - 180 minutes
The difference in the three-hour Tmax (0 - 180 min) of intravenous glucose and insulin between Good IdeaTM and the placebo following a standardized meal.	0 - 180 minutes
The difference in the three-hour iAUC (0 - 180 min) of capillary glucose between Good IdeaTM and the placebo following a standardized meal.	0 - 180 minutes
The difference in the three-hour (0 - 180 min) Tmax of capillary glucose between Good IdeaTM and the placebo following a standardized meal.	0 - 180 minutes
The difference in the three-hour (0 - 180 min) Cmax, of capillary glucose between Good IdeaTM and the placebo following a standardized meal.	0 - 180 minutes
Eating patterns as assessed by a 3-day food record for the weeks prior to days 0 and 8.	1 week each

Other Outcome Measures

Outcome Measure	Time Frame
The effects of supplementation with Good IdeaTM on vital signs (blood pressure) compared to placebo	180 minutes
The effects of supplementation with Good IdeaTM on vital signs (heart rate) compared to placebo	180 minutes
The change in Hematology from screening to end-of-study between Good IdeaTM and the placebo	21 - 42 days
The change in Clinical chemistry from screening to end-of-study between Good IdeaTM and the placebo	21-42 days
Incidence of adverse events in the Good IdeaTM and placebo group over the course of the study.	8-14 days

Collaborators and Investigators

• Sponsor: DoubleGood AB
• Collaborators: KGK Science Inc.

Publications and helpful links

General Publications

• Östman E, Samigullin A, Heyman-Lindén L, Andersson K, Björck I, Öste R, Humpert PM. A novel nutritional supplement containing amino acids and chromium decreases postprandial glucose response in a randomized, double-blind, placebo-controlled study. PLoS One. 2020 Jun 24;15(6):e0234237. doi: 10.1371/journal.pone.0234237. eCollection 2020.

Study record dates

Study Major Dates

• Study Start (Actual): April 22, 2017
• Primary Completion (Actual): August 15, 2017
• Study Completion (Actual): August 15, 2017

Study Registration Dates

• First Submitted: May 9, 2017
• First Submitted That Met QC Criteria: May 12, 2017
• First Posted (Actual): May 15, 2017

Study Record Updates

• Last Update Posted (Actual): November 22, 2022
• Last Update Submitted That Met QC Criteria: November 17, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: glucose homeostasis; glucose
• Other Study ID Numbers: 17GGHD

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No